ArticleAAPS PharmSciTech2026
Advancing Rare Cancer Therapeutics: Osimertinib-Loaded Inhaled PLGA Nanoparticles for Mesothelioma Treatment.
Article in AAPS PharmSciTech, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite advances in mesothelioma treatment, malignant pleural mesothelioma (MPM) continues to present a poor prognosis due to its aggressive progression and resistance to conventional therapies. Current treatment modalities, including surgery, chemotherapy, radiation, and immunotherapy, offer limited efficacy, with a five-year survival rate of approximately 12%. To address the limitations of systemic drug delivery, this study investigates the therapeutic potential of osimertinib (OSI), a third-generation tyrosine kinase inhibitor, delivered via inhalation using poly(lactic-co-glycolic acid) (PLGA) nanoparticles. The optimized PLGA-OSI formulation exhibited an encapsulation efficiency of 43.1 ± 4.8%, drug loading of 4.4 ± 0.4%, particle size of 198.5 ± 9.3 nm, and zeta potential of -17.6 ± 1.2 mV. In vitro cytotoxicity assays revealed IC₅₀ values of 13.5 ± 0.1 µM (MSTO-211H), 27.7 ± 0.3 µM (H2452), and 8.1 ± 0.2 µM (H226) after 48 h. Compared to free OSI, PLGA-OSI enhanced cellular uptake, increased GFP-positive cells by 1.7-fold, and elevated fluorescence intensity by 5.3-fold. Clonogenic and scratch assays confirmed significant inhibition of cell proliferation and migration. Moreover, spheroid models demonstrated superior tumor suppression with multi-dose treatments. These findings highlight the potential of inhaled PLGA-OSI nanoparticles to improve drug delivery and therapeutic outcomes in MPM, supporting their further development as a targeted treatment strategy against this challenging malignancy.
Indexed as
Identifiers
41775929What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.